Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    11004621 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Efalizumab for Moderate to Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Intervention: Drug: Raptiva

Indicates status has not been verified in more than two years